Akervall J A, Michalides R J, Mineta H, Balm A, Borg A, Dictor M R, Jin Y, Loftus B, Mertens F, Wennerberg J P
Department of Otorhinolaryngology/Head and Neck Surgery, University Hospital, Lund, Sweden.
Cancer. 1997 Jan 15;79(2):380-9.
Abnormalities of chromosome band 11q13 are frequent in squamous cell carcinoma of the head and neck (SCCHN). The oncogene CCND1 is located at 11q13 and encodes cyclin D1, a cell cycle-regulating protein. The authors investigated the clinical relevance and associations between amplification and overexpression of cyclin D1 and 11q13 rearrangements.
The study involved two series of patients. In Series 1, overexpression of cyclin D1 and 11q13 rearrangements, assessed by immunohistochemistry and cytogenetics, respectively, were compared with clinical data in 75 patients with SCCHN. Patients were monitored for at least 18 months or until death. In another 23 patients (Series 2), the authors investigated the association between DNA amplification (by slot blot hybridization), overexpression of cyclin D1, and cytogenetics.
In Series 1, 9 of 75 tumors (12%) had 11q13 aberrations, 6 of which manifested elevated expression of cyclin D1. Patients with tumors strongly positive for cyclin D1 (n = 9) and those with tumors showing 11q13 rearrangements had poorer survival (P = 0.047 and 0.005, respectively). However, the correlation between these two variables was weak (P = 0.12). In Series 2, 17 of 23 tumors (74%) showed elevated cyclin D1 protein expression, and 6 of these showed gene amplification as well. Of these six, only one revealed 11q13 rearrangements.
Overexpression of cyclin D1 and 11q13 rearrangements are independent prognostic factors for SCCHN. In general, DNA amplification results in overexpression of cyclin D1, but additional genetic mechanisms are involved in the deregulation. Furthermore, oncogenes at 11q13 besides CCND1 may be involved in the tumorigenesis.
11q13染色体异常在头颈部鳞状细胞癌(SCCHN)中很常见。癌基因CCND1位于11q13,编码细胞周期调节蛋白细胞周期蛋白D1。作者研究了细胞周期蛋白D1的扩增和过表达与11q13重排之间的临床相关性及关联。
该研究纳入了两组患者。在第一组中,分别通过免疫组织化学和细胞遗传学评估的细胞周期蛋白D1过表达和11q13重排与75例SCCHN患者的临床数据进行了比较。对患者进行了至少18个月的监测或直至死亡。在另外23例患者(第二组)中,作者研究了DNA扩增(通过斑点杂交)、细胞周期蛋白D1过表达与细胞遗传学之间的关联。
在第一组中,75个肿瘤中有9个(12%)存在11q13畸变,其中6个表现为细胞周期蛋白D1表达升高。细胞周期蛋白D1强阳性的肿瘤患者(n = 9)和显示11q13重排的肿瘤患者的生存率较低(分别为P = 0.047和0.005)。然而,这两个变量之间的相关性较弱(P = 0.12)。在第二组中,23个肿瘤中有17个(74%)显示细胞周期蛋白D1蛋白表达升高,其中6个也显示基因扩增。在这6个中,只有1个显示11q13重排。
细胞周期蛋白D1过表达和11q13重排是SCCHN的独立预后因素。一般来说,DNA扩增导致细胞周期蛋白D1过表达,但还涉及其他遗传机制的失调。此外,11q13上除CCND1之外的癌基因可能参与肿瘤发生。